NCT05258279View on ClinicalTrials.gov

Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR Mutations

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 1, 2022

Primary Completion Date

October 31, 2023

Study Completion Date

October 31, 2024

Conditions
Non-squamous Non-small-cell Lung CancerEGFR Activating Mutation
Interventions
DRUG

Pembrolizumab

IV infusion Q3W

DRUG

Lenvatinib

Oral capsule once daily

DRUG

Carboplatin

IV infusion Q3W

DRUG

Pemetrexed

IV infusion Q3W

Trial Locations (10)

279-0021

Juntendo Urayasu Hospital, Urayasu

216-8511

St. Marianna University Hospital, Kawasaki

236-0051

Kanagawa Cardiovascular and Respiratory Center, Yokohama

241-8515

Kanagawa Cancer Center, Yokohama

350-1298

Saitama Medical University International Medical Center, Hidaka

362-0806

Saitama Cancer Center, Shinden

411-8777

Shizuoka Cancer Center, Nagaizumi-cho

113-8431

Juntendo University Hospital, Bunkyo-ku

113-8677

Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo-ku

26-8677

Chiba University Hospital, Chiba

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Juntendo University

OTHER